0
New
New
2023
Neurointerventional Devices Market

Neurointerventional Devices Market by Product (Stents, Embolic Coils, Catheter, Wires, Others), by Indication (Brain Aneurysm, Stroke, Others), by Application (Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A14456
Pages: 282
Jun 2023
Author(s) : Linu Dash, Digvijay Gawali , Onkar Sumant
Tables: 134
Charts: 72
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

Loading Table Of Content...


 
 

Neurointerventional devices are medical devices used in the field of neurointerventional radiology to diagnose and treat various conditions affecting the blood vessels of the brain and spinal cord. These devices are designed to access the blood vessels through minimally invasive procedures, such as catheterization, and deliver targeted treatments directly to the affected areas. Some common interventional treatments include embolization, thrombectomy, angioplasty, and stenting. The strategies such as product launch and acquisition adopted by key players are expected to drive the growth of the market.

In March 2023, Johnson & Johnson, an American multinational company, announced the launch of new CEREPAK Detachable Coils in the U.S. The CEREPAK Detachable Coils offer three shapes and multiple coil sizes, providing physicians with comprehensive options to embolize brain aneurysms, including coils shaped, specifically to achieve concentric aneurysm filling and contribute large volumetric filling. In June 2023, BIOTRONIK, a leading medical devices company, announced the limited release of its Oscar (One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter.

In April 2022, Integer Holdings Corporation, a leader in advanced medical device outsourcing, announced the acquisition of Connemara Biomedical Holdings Teoranta, including its acquisition transferred ownership of Aran Biomedical and Proxy Biomedical to Integer Holdings Corporation. Aran Biomedical and Proxy Biomedical were operating subsidiaries of Connemara Biomedical Holdings Teoranta. The acquisition with Aran Biomedical further increases Integer’s ability to offer complete solutions for complex delivery and therapeutic devices in high-growth cardiovascular markets such as structural heart, neurovascular, peripheral vascular, and endovascular as well as general surgery.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save the time of readers